Loxo & Illumina team up for diagnostic tool targeting cancer

Loxo Oncology and Illumina are partnering up on a diagnostic tool, seeking approval for a version of Illumina’s test, TruSight Tumor 170, which will let local labs provide referring physicians with genomic information and have patients be better matched to appropriate therapeutic options.

Larotrectinib directly targets an acquired genetic defect called TRK fusions, which triggers accelerated cancer cell growth in patients. Up to 5,000 U.S. patients a year are diagnosed with the TRK defect.

Read the Reuters report